Monoclonal antibody · Agonist of dectin-2 (CLEC6A) · developed by Bolt Biotherapeutics
BDC-3042 is an agonistic monoclonal antibody that binds and activates dectin-2 (CLEC6A), an activating C-type lectin receptor expressed by tumor-associated macrophages in the tumor microenvironment. Activation is intended to repolarize these macrophages toward an immunostimulatory state and promote T-cell-mediated anti-tumor immunity. It is being studied in multiple solid tumors, including triple negative breast cancer, renal cell carcinoma, ovarian cancer, head and neck cancer, colorectal cancer, non-small cell lung cancer and melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06052852 | Phase 1 | Triple Negative Breast Cancer | Terminated | BOLT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clear Cell Renal Cell CarcinomaColorectal CancerHead and Neck CancerMelanomaNon-small Cell Lung CancerOvarian CancerTriple Negative Breast Cancer
See BOLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BOLT catalysts and pipeline →